JNJ · News · 20261014N
Revenue Performance and Mix
JOHNSON & JOHNSON · 2026-10-14 · Importance 42 · Surprise 14 · In source text
Johnson & Johnson reported third-quarter 2026 revenue of $25.40 billion, slightly below the $25.44 billion consensus estimate, while adjusted EPS of $2.59 exceeded the $2.53 estimate. Innovative Medicine sales increased 7.7% year over year, outperforming MedTech, where sales rose 2.5% to $8.64 billion. MedTech growth was below management’s internal expectations because of weakness in international markets and at Abiomed, while stronger Innovative Medicine growth supported a higher full-year 2026 outlook.
Key facts
- Revenues for Q3 2026 were $25.40 billion, which fell slightly below the consensus estimate of $25.44 billion. source
- Quarterly adjusted earnings were $2.59 per share for Q3 2026, exceeding the Zacks Consensus Estimate of $2.53. source
- Johnson & Johnson's shares declined around 5.8% on Tuesday following its third-quarter 2026 results. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | negative | realized | — | Revenues for Q3 2026 were $25.40 billion, which fell slightly below the consensus estimate of $25.44 billion. |